Leap Therapeutics Stock Is Moving Higher On Updated DKN-01 Combo Trial Data In Gastric Cancer

Leap Therapeutics Inc LPTX announced updated data from the first-line cohort of the DisTinGuish Phase 2a trial evaluating DKN-01 combined with BeiGene Ltd’s BGNE tislelizumab and chemotherapy in gastric or gastroesophageal junction cancer (G/GEJ).
The data were presented at the European Society for Medical Oncology (ESMO21) Congress. Earlier this week, the Company announced initial data from the DisTinGuish study based on 25 G/GEJ patients.
Related Content: Why Are Leap Therapeutics Shares Trading Higher On Monday?
The results presented today included additional patient data stratified by tumoral PD-L1 expression levels.
The response was independent of PD-L1 expression and particularly strong in the less favorable to checkpoint inhibitor therapy, PD-L1 low population.
Among those patients with PD-L1-low expression, the ORR was 79%, with 100% in DKK1-high patients and 57% in DKK1-low patients.
Among those patients with PD-L1-high expression, the ORR was 67%, with 75% ORR in DKK1-high patients and 50% in DKK1-low patients.
The median duration of response and progression-free survival data are not yet mature, and patient follow-up continues.
Of the 25 patients, 15 patients had experienced a partial response (PR), six patients had the best response of stable disease (SD), one patient was non-evaluable for response (NE), and three patients were unable to complete a full cycle of DKN-01 therapy.
Price Action: LPTX shares are up 30.60% at $2.52 during the premarket session on the last check Thursday.
Check out our coverage of the European Society for Medical Oncology Congress (ESMO21)

Market News and Data brought to you by Benzinga APIs

Comments

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga